Kaempferol Inhibits Hepatic Stellate Cell Activation by Regulating miR-26b-5p/Jag1 Axis and Notch Pathway

Kaempferol, a natural flavonoid molecule, has demonstrated anti-inflammatory, antimicrobial and antioxidant activities. Recent studies have shown the beneficial effects of kaempferol on liver fibrosis. Notch pathway has been reported to be involved in the aberrant activation of hepatic stellate cells (HSCs). However, whether Notch pathway plays a key role in the anti-fibrotic effects of kaempferol is largely unknown. In this study, kaempferol significantly suppressed liver fibrosis in CCl₄ mice, with reduced collagen deposition as well as restored liver function. In vitro, kaempferol enhanced the suppression of HSC activation, with a decrease in α-SMA as well as collagen level. It was found that Notch pathway played an important role in kaempferol-reduced the activation of HSCs. Jag1, a ligand of Notch pathway, was obviously inhibited by kaempferol. Overexpression of Jag1 effectively abolished kaempferol-induced HSC inactivation. Furthermore, Jag1 was demonstrated as a target of microRNA-26b-5p (miR-26b-5p). Interestingly, miR-26b-5p inhibitor prevented HSC activation inhibition caused by kaempferol. Further studies indicated that kaempferol inhibited Notch pathway via miR-26b-5p and Jag1, leading to HSC inactivation. Collectively, we demonstrate that kaempferol could inhibit HSC activation, at least in part, via miR-26b-5p-mediated Jag1 axis and Notch pathway. Kaempferol may serve as a promising drug in the application of treating liver fibrosis.

Introduction

Liver fibrosis, as a diffuse disease caused by various liver injury, is a common pathological process of chronic liver diseases. Currently, liver fibrosis is mainly induced by hepatitis virus infection or alcoholism, resulting in a rock-ribbed health problem worldwide (Ueha et al., 2012). The main characteristics of liver fibrosis are excessive extracellular matrix (ECM) proteins including type I collagen. In response to sustained inflammatory stimuli and chronic injury, hepatic stellate cells (HSCs) undergo “activation” and transform from store vitamin A cells into proliferating, migrating and contracting myofibroblasts, which is considered as a key event in the development of liver fibrosis (Faraj et al., 2011; Tokunaga et al., 2017). Therefore, effectively down-regulating HSC activation is one of promising therapeutic strategies for ameliorating liver fibrosis.

MicroRNAs (miRNAs) are a class of non-coding RNAs with a length of 20–24 nt (Zeng et al., 2019). In general, miRNAs negatively regulate gene expression via targeted mRNA cleavage or translation inhibition at the post-transcriptional level (Elovic et al., 2019). Recent studies have demonstrated that miRNAs participate in cellular biological functions such as proliferation and apoptosis (Kitano and Bloomston, 2016). Deregulated miRNAs are widely found in various human diseases including cancers, which may contribute to the progression of diseases (Sharma et al., 2021). Yang et al. revealed that miR-26b-5p acts as an antifibrotic miRNA in liver fibrosis via targeting PDGFR-β (Yang et al., 2019). We previously demonstrated that pinostilbene hydrate-induced HSC inactivation is through miR-17-5p and WIF1 (Zhou et al., 2020). Combined with these, miRNAs play an irreplicable role in the regulation of HSC activation, and targeting liver fibrosis-related miRNAs may be one of the promising treatment strategies.

Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one), a natural flavonoid molecule, is widely present in fruits, vegetables and traditional herbs (Kim et al., 2018; Ren et al., 2019). Kaempferol has demonstrated anti-inflammatory, antimicrobial and antioxidant activities (Rho et al., 2011). Recently, Li et al. demonstrated that kaempferol contributes to the suppression of collagen synthesis, proliferation and activation of fibroblasts in hypertrophic scar (HPS) (Li et al., 2016). Interestingly, Xu et al. found that kaempferol-ameliorated liver fibrosis may be via activin receptor-like kinase 5 (Xu et al., 2019). However, the potential molecular mechanisms of kaempferol in the regulation of liver fibrosis progression are still largely unknown. Herein, it was found that kaempferol ameliorated the development of liver fibrosis in vivo as well as in vitro. Kaempferol was shown to suppress the activation of HSCs, at least in part, via miR-26b-5p-mediated Notch pathway.

Materials and Methods

Materials

MiRNA negative control (miR-NC), miR-26b-5p mimics/inhibitor, adenoviral vectors expressing Jag1 (Ad-Jag1), adenoviral vectors expressing a control scrambled sequence (Ad-Ctrl), adenoviral vectors expressing shRNA against Jag1 (Ad-shJag1) and adenoviral vectors expressing the scrambled shRNA (Ad-shCtrl) were obtained from GenePharma biotechnology (Shanghai, China). The molecular weight and molecular formula of kaempferol (≥97% purity, Sigma, St Louis, MO, United States) are 286.24 and C₁₅H₁₀O₆, respectively (Figure 1A).

FIGURE 1

FIGURE 1. Kaempferol alleviates liver fibrosis caused by CCl₄ in vivo. (A) The chemical structure of kaempferol. (B) Analysis of Sirius Red staining for collagen deposits. Scale bar, 100 μm. (C) Analysis of α-SMA immunohistochemistry. Scale bar, 100 μm. (D) Hydroxyproline level. (E) Serum ALT level. (F) Serum AST level. *p < 0.05 compared with the control and ^#p < 0.05 compared with CCl₄ group.

Animal Experiments

Liver fibrosis was produced by intraperitoneal injection with carbon tetrachloride (CCl₄) (Sigma, St Louis, MO, United States) in olive oil (10%, 7 μL/g mice) two times weekly for 4 weeks in 8-week-old C57BL/6 J mice (n = 6). Meanwhile, mice in control group were given the same volume of olive oil (n = 6). In kaempferol group, mice (n = 6) were treated with kaempferol (10 μmol/L, 1 ml) daily via intraperitoneal injection during CCl₄ period (Xu et al., 2019). This project was approved by the University Animal Care and Use Committee of Wenzhou Medical University. Mice, obtained from the Experimental Animal Center of Wenzhou Medical University, were sacrificed under anesthesia after the end of animal experiment. Finally, blood samples and liver tissues were collected for further analysis such as Sirius red staining.

Immunohistochemistry

Briefly, the tissues were immersed in 4% formalin for fixation, and then the formalin-fixed tissue is degreased and rehydrated. Next, the sections, blocked in 10% BSA, were in the incubation with anti-α-SMA primary antibody at 4°C for at least 12 h. Then, the sections were incubated with a horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody for 30 min. Finally, quantitative analysis for α-SMA-positive areas was performed under the microscope (Carl Zeiss, Germany).

Hepatic Hydroxyproline Content

According to the manufacturer’s instructions, the hydroxyproline content in liver tissue was measured using the Hydroxyproline Colorimetric Assay kit (BioVision, San Francisco, CA) and liver weight was used to normalize the relative abundance of hydroxyproline. Briefly, liver tissues were mixed with HCl for homogenization, and then hydrolyzed for 12 h. The supernatant was obtained from the lysate, which was centrifuged at 12,000 g for 10 min at 4°C.

Primary HSCs Isolation and Culture

According to the previously described enzyme digestion and density gradient centrifugation, isolated primary HSCs were obtained (Chang et al., 2014). The purity of primary HSCs was >98%, which was defined by α-SMA and Desmin immunocytochemical staining. Primary 1-day-old HSCs were treated with 10 μM kaempferol or 20 μM curcumin (Cur) for 24 h, respectively. Cells were transfected with 100 nM miR-26b-5p mimic using lipofectamine RNAiMAX.

Signaling Pathway Assay

The Cignal Finder 10-Pathway Reporter Array (QIAGEN, MA, United States) was performed to determine the kaempferol-related signaling pathways. Attractene (1 μL/well) was distributed into Cignal Finder 10-Pathway Reporter Array plate. Then, primary HSCs cell suspension was diluted in Opti-MEM medium and seeded in each well. Cells were treated with 10 μM kaempferol on the following day. After 24 h of treatment, reverse transfection reagent and Opti-MEM medium were removed. Dual-Glo Luciferase Reagent (75 μL) was then added to each well and plates were incubated for 10 min at room temperature. Finally, firefly and Renilla luciferase activities were measured following the manufacturer’s recommendations.

Quantitative Real-Time PCR Analysis

Total RNA was isolated from primary HSCs as well as liver tissues using the Tiangen RNA extraction reagent kit. Each sample (1 µg RNA) was reversely transcribed into complementary DNA (cDNA) using a reverse-transcription (RT) reagent kit (Takara Biotechnology Co., Ltd., Dalian, China). Then, Real-time PCR was performed using SYBR Premix ExTaq (Takara). As shown in Supplementary Table S1, the primers of α-SMA, alpha-1(I) collagen (Col1A1), hes family bHLH transcription factor 1 (Hes1), Hes5, Notch1-4, Delta-like 1 (Dll1), Dll3, Dll4, Jagged 1 (Jag1), Jag2 and GAPDH were designed. TaqMan MicroRNA Assays (Applied Biosystems, Foster City, CA) were performed to detect 10 miRNAs expressions. GAPDH and U6 were used as endogenous controls for mRNAs and for miRNAs, respectively.

Western Blot Analysis

The proteins from primary HSCs and liver tissues were extracted using RIPA extraction buffer. The protein samples of interested were separated by 10% SDS-PAGE electrophoresis, and then transferred to PVDF membranes. The primary anti-Jag1, anti-α-SMA, type I collagen and anti-GAPDH (an internal control) were added in PVDF membranes and incubated overnight at 4°C. Then, the second antibody was added and incubated at room temperature for 1 h.

Immunofluorescence

In brief, cells were fixed in 4% paraformaldehyde for 20 min at room temperature, and then permeabilized with PBS-0.5% Triton X-100 for 15 min. Subsequently, blocking with 5% BSA in PBS for 1 h at 37°C and incubated with the following primary antibodies overnight at 4°C in a humidified chamber: anti-α-smooth muscle actin (α-SMA) (1:100) and anti-type I collagen (1:100). On the next day, the cells were incubated with secondary antibodies conjugated with Alexa Fluor 488 or 546 (Invitrogen), respectively. Nuclei were stained using 4,6-diamidino-2-phenylindole (DAPI), and cells were observed using a Nikon Eclipse Ti-E inverted fluorescence microscope (Nikon, Tokyo, Japan).

5-Ethyny-2ʼ-Deoxyuridine Assay

EdU assay was used to detect cell proliferation. After kaempferol or Cur treatment, cells were labeled with EdU for 12 h, and EdU⁺ population represented the proliferating cell population.

Luciferase Reporter Assay

As described previously, miR-26b-5p or miR-NC was co-transfected with pmirGLO-Jag1 into HEK293T cells by lipofectamine-mediated gene transfer (Yu et al., 2017). After 24 h, the luciferase signals were detected using the Dual-Luciferase^® Reporter Assay System (Promega). Firefly luciferase intensity was normalized over Renilla luciferase signal.

Statistical Analysis

Data were presented as the means ± SD. One-way analysis of variance (one-way ANOVA) was employed for multiple groups. Differences between two groups were compared using student’s t-test. p < 0.05 was considered significant. The SPSS software was used for all statistical analyses (version 16.0; SPSS, Chicago, IL).

Results

Kaempferol Alleviates Liver Fibrosis Caused by CCl₄ in vivo

The roles of kaempferol were firstly examined in CCl₄-induced mouse liver fibrosis model. As shown by Sirius red staining and immunohistochemical analysis, both collagen deposition and α-SMA expression were induced by CCl₄, respectively (Figures 1B,C). Hydroxyproline assays further confirmed enhanced collagen level by CCl₄ (Figure 1D). Liver function of CCl₄ mice was shown to be injured, associated with increased ALT and AST (Figures 1E,F). Notably, kaempferol significantly inhibited CCl₄-caused collagen (Figures 1B,D). Kaempferol resulted in the reduction in α-SMA expression (Figure 1C). Furthermore, kaempferol ameliorated liver function (Figures 1E,F). Our results demonstrate that kaempferol ameliorates CCl₄-induced liver fibrosis in vivo.

Kaempferol Decreases the Activation of HSCs

Whether kaempferol contributed to the suppression of HSC activation was subsequently investigated. Cur, which has been demonstrated to suppress HSC activation, was used as a positive control (Zhang et al., 2014). Obviously, Cur inhibited HSC proliferation, HSC transdifferentiation as well as collagen expression. Our results showed that Cur induced a significant reduction in HSC proliferation, HSC transdifferentiation and collagen level (Figures 2A–C). As shown by Edu assays, kaempferol caused no significant change in cell proliferation (Figure 2A). Kaempferol obviously inhibited HSC transdifferentiation, with reduced α-SMA mRNA level (Figure 2B). Moreover, kaempferol resulted in the suppression of Col1A1 mRNA level (Figure 2C). Accordingly, immunoblot results indicated that both α-SMA protein and type I collagen were inhibited by kaempferol (Figure 2D). Overall, the above data suggest that kaempferol plays an inhibitory role in the activation of HSCs.

FIGURE 2

FIGURE 2. Effects of kaempferol on HSC proliferation and activation. Primary 1-day-old HSCs were treated with 10 μM kaempferol for 24 h. (A) Cell proliferation. (B) α-SMA mRNA. (C) Col1A1 mRNA. (D) Levels of α-SMA protein and type I collagen. **p < 0.01 compared with the control.

Kaempferol Promotes HSC Activation Inhibition Via Down-Regulating Jag1

Next, the underlying molecular mechanism of kaempferol in the regulation of HSC activation was examined. A pathway reporter array was used to rapidly identify the relevant pathways in cells with kaempferol. Clearly, kaempferol resulted in an obvious suppression in six signaling pathways including TGF-β, Notch, NF-κB, MAPK/JNK, MAPK/ERK and Wnt, with the lowest expression in Notch pathway (Figure 3A). Our results suggest that the Notch pathway may take a part in the effects of kaempferol-inhibited HSC activation (Figure 3A). Subsequently, Hes1 and Hes5, which are the downstream of the Notch pathway, were examined in cells after kaempferol treatment. In comparison with non-treated cells, kaempferol induced a significant reduction in the mRNA expressions of Hes1 and Hes5 (Figure 3B). Accordingly, the protein levels of Hes1 and Hes5 were down-regulated by kaempferol (Figure 3C). Generally, Notch signaling is initiated by the activated Notch receptors and ligands (Kovall et al., 2017). In kaempferol-treated cells, the expressions of Notch receptors as well as ligands were measured. Our results showed that the level of Jag1 was reduced after kaempferol treatment, whereas others not (Figure 3D). Consistent with the mRNA result, Jag1 protein was also decreased in kaempferol-treated cells (Figure 3E), indicating that Jag1 may participate in the effects of kaempferol on HSC activation inhibition. Thus, Jag1 expression was detected in vitro and in vivo during HSC activation. It was found that Jag1 expression was obviously enhanced in primary HSCs during cell culture, which was inhibited by kaempferol (Figures 3F,G). Similar with the results in vitro, Jag1 expression was up-regulated in CCl₄ mice, which was also suppressed by kaempferol (Figures 3H,I). Whether Jag1 plays a key role in the inhibitory effects of kaempferol on the activation of HSCs was further explored. As shown in Figure 4A and Supplementary Figure S1, overexpression of Jag1 was found in Ad-Jag1 group, while loss of Jag1 was shown in Ad-shJag1 group. Compared with kaempferol group, the change of proliferative activity between Ad-Jag1 and Ad-shJag1 group was no significant (Figure 4B). Interestingly, overexpression of Jag1 blocked down kaempferol-inhibited α-SMA and Col1A1 (Figures 4C,D). On the contrary, loss of Jag1 enhanced the inhibition of α-SMA and Col1A1 in kaempferol-treated cells (Figures 4E,F). Additionally, analysis of immunofluorescence confirmed that kaempferol-reduced type I collagen (green fluorescence) and α-SMA (red fluorescence) was blocked down by Ad-Jag1 (Figure 4G and Supplementary Figure S2A). These data suggest that the inhibitory role of kaempferol in the regulation of HSC activation is via suppressing Jag1, leading to the inactivation of Notch pathway.

FIGURE 3

FIGURE 3. Kaempferol inhibits HSC activation through Notch pathway. Primary 1-day-old HSCs were treated with 10 μM kaempferol for 24 h. (A) Signaling pathway reporter array was performed to search for kaempferol-related pathways. mRNA (B) and protein (C) expressions of Hes1 and Hes5. Three experiments with similar outcome. (D) mRNA expressions of Notch receptors and ligands. (E) Jag1 protein level in kaempferol-treated cells. mRNA (F) and protein (G) expressions of Jag1 in primary HSCs during cell culture. mRNA (H) and protein (I) expressions of Jag1 in CCl₄ mice. **p < 0.01, ***p < 0.01 compared with the control. ^#p < 0.05, ^##p < 0.01 compared with the Day4 or CCl₄ group.

FIGURE 4

FIGURE 4. Kaempferol inhibits HSC activation via down-regulating Jag1. Primary 1-day-old HSCs were treated with 10 μM kaempferol for 24 h and then transduced with Ad-Jag1/Ad-shJag1 for additional 24 h (A) Jag1 expression. (B) Cell proliferation. mRNA (C) and protein (D) expressions of α-SMA and Col1A1 in cells with Jag1 overexpression. mRNA (E) and protein (F) expressions of α-SMA and Col1A1 in cells with Jag1 knockdown. (G) Immunofluorescence staining for α-SMA (red) and type I collagen (green). DAPI stained nuclei blue. **p < 0.01, ***p < 0.01 compared with the control, and ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 compared with kaempferol group.

Jag1 is a Target of miR-26b-5p

Recently, miRNA-mediated Jag1 expression has been found in various human diseases (Zhang et al., 2020a; Zhang et al., 2020b). Herein, bioinformatics analysis (miRDB) was performed to identify the potential miRNAs targeting Jag1, and 10 miRNAs with the highest target score were shown in Figure 5A. Interestingly, in kaempferol-treated cells relative to the untreated cells, only miR-26b-5p was significantly up-regulated, whereas other predicted miRNAs not (Figure 5B). Therefore, miR-26b-5p was selected for the next experiments. Both in vitro and in vivo, the levels of miR-26b-5p were examined during liver fibrosis. Our results showed that reduced miR-26b-5p was found in primary HSCs at Day 4 as well as CCl₄ mice (Figure 5C), indicating that the miR-26b-5p was negatively correlated with the Jag1. Thus, the Jag1 target region was cloned in the pmirGLO plasmid to generate a Jag1 pmirGLO luciferase reporter containing the miR-26b-5p binding sites (Figure 5D). Luciferase activity assays were performed to determine whether Jag1 is a target of miR-26b-5p. Clearly, miR-26b-5p induced a significant reduction in luciferase activity driven by the wild-type 3′UTR of Jag1, and there was no significant difference in mutant-type 3′UTR of Jag1 (Figure 5E). In primary HSCs, miR-26b-5p overexpression down-regulated Jag1 mRNA as well as protein expression (Figures 5F,G). Our data suggest that miR-26b-5p induced by kaempferol targets Jag1.

FIGURE 5

FIGURE 5. Jag1 is a target of miR-26b-5p. (A) 10 predicted miRNAs with the highest target score were shown in bioinformatics analysis (miRDB). (B) miR-26b-5p was enhanced in cells with kaempferol. (C) miR-26b-5p level in vitro and in vivo. (D) miR-26b-5p-biding sites in the 3′UTR of Jag1 mRNA based on miRDB software. (E) Relative luciferase activities of luciferase reporters bearing wild-type or mutant Jag1 were analyzed 48 h following transfection with the indicated miR-26b-5p mimics or miR-NC in HEK293T cells. Jag1 mRNA (F) and protein (G) expression in cells with miR-26b-5p. *p < 0.05, **p < 0.01 compared with the control.

Kaempferol Suppresses HSC Activation Through miR-26b-5p-Mediated Jag1 Axis

Whether miR-26b-5p plays a crucial role in the inhibitory effects of kaempferol on HSC activation was further investigated. After transfection with miR-26-5p inhibitor, the proliferation of kaempferol-treated cells was detected by EdU analysis. In line with our previous results, miR-26-5p had no effect on cell proliferation in comparison with kaempferol group (Figure 6A). Notably, loss of miR-26-5p blocked down kaempferol-reduced α-SMA mRNA expression (Figure 6B). Likewise, miR-26-5p inhibitor significantly suppressed kaempferol-inhibited Col1A1 expression (Figure 6C). Accordingly, the results of immunoblot indicated that miR-26-5p inhibitor restored α-SMA and type I collagen in cells with kaempferol (Figure 6D). Results of immunofluorescence further revealed that miR-26-5p inhibitor contributed to the restoration of α-SMA and type I collagen in kaempferol-treated cells (Figure 6E and Supplementary Figure S2B). Moreover, kaempferol-inhibited Jag1 was restored by miR-26b-5p inhibitor (Figures 6F,G). Therefore, kaempferol suppresses HSC activation, at least in part, through miR-26b-5p-mediated Jag1 axis.

FIGURE 6

FIGURE 6. Kaempferol suppresses HSC activation through miR-26b-5p-mediated Jag1 axis. Primary 1-day-old HSCs were treated with 10 μM kaempferol for 24 h and then transfected with 100 nM miR-26b-5p inhibitor for additional 24 h. (A) Cell proliferation. (B) α-SMA mRNA level. (C) Col1A1 mRNA level. (D) Protein expressions of α-SMA and Type I collagen in kaempferol-treated HSCs after miR-26b-5p inhibitor treatment. (E) Immunofluorescence staining for α-SMA (red) and type I collagen (green). DAPI stained nuclei blue. (F,G) Jag1 mRNA and protein were detected in kaempferol-treated HSCs after miR-26b-5p inhibitor treatment. Three experiments with similar outcome. **p < 0.01 compared with the control, and ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 compared with kaempferol group.

Discussion

Kaempferol has been demonstrated to have many properties in various human diseases. One of the well-known properties of kaempferol is anti-inflammation. Previously, Gong et al. found that kaempferol inhibits the progression of airway inflammation via down-regulating NF-κB pathway (Gong et al., 2012). Besides, increasing studies have shown the beneficial effects of kaempferol on cancers including hepatocellular carcinoma (Guo et al., 2016). Recently, it has been reported that kaempferol has beneficial effects against fibroproliferative disorders including liver fibrosis and HPS. For instance, kaempferol suppresses TGF-β/Smads signalling in liver fibrosis via directly binding to the catalytic region of ALK5 (Xu et al., 2019). However, the detailed mechanisms of kaempferol against liver fibrosis are still unknown. In this study, kaempferol was found to have beneficial effects against liver fibrosis both in vivo and in vitro, associated with the downregulated expressions of α-SMA level and collagen. In addition, CCl₄-induced serum ALT/AST level was inhibited by kaempferol, indicating that kaempferol treatment contributes to the restoration of liver function during liver fibrosis. Further studies confirmed that miR-26b-5p-mediated Notch pathway was highly correlated with the beneficial effects of kaempferol on liver fibrosis. Owing to the restoration of miR-26b-5p, Jag1 level was inhibited, leading to the suppression of Notch pathway, which finally resulted in the inhibition of HSC activation. Our results demonstrate that kaempferol inhibits HSC activation, at least in part, via miR-26b-5p/Jag1 axis, and this is a first report.

The Notch pathway, a highly conserved signalling, has been shown to play critical roles in animal development, tissue homeostasis and human diseases (Artavanis-Tsakonas and Muskavitch, 2010; Siebel and Lendahl, 2017). There are four Notch receptors (NOTCH1-4) and five canonical ligands (DLL1, DLL3, DLL4, JAG1 and JAG2) in mammals. Notch pathway is essential to various cellular processes such as cell fate specification, proliferation and apoptosis (Bray, 2016). Emerging evidence has shown that aberrant Notch pathway activation contributes to the initiation and progression of cancers (Villanueva et al., 2012). Activated Notch pathway is also involved in human fibrotic diseases including liver fibrosis (Geisler and Strazzabosco, 2015). Recent studies have shown that during HSC activation, Jag1 expression is enhanced in rat HSCs (Sawitza et al., 2009). Tang et al. further confirmed that loss of Jag1 pathway results in the suppression of HSC activation (Tang et al., 2017). Herein, it was found that Notch pathway was significantly inhibited by kaempferol, associated with reduced Hes1 and Hes5. Similar with the previous studies, Jag1 expression was enhanced during liver fibrosis, which was obviously down-regulated by kaempferol. In addition, Jag1 overexpression blocked down the effects of kaempferol on HSC activation inhibition, whereas loss of Jag1 had opposite effects. In sum, kaempferol inhibits HSC activation via Jag1-mediated Notch pathway.

MiR-26b-5p, a member of miR-26 family, functions as a human tumor suppressor. For example, miR-26b-5p, down-regulated in breast cancer, induces breast cancer cell apoptosis via targeting SLC7A11 (Liu et al., 2011). Importantly, miR-26b-5p is involved in a series of pathophysiological processes such as angiogenesis and inflammation. Increasing evidence has shown that miR-26b-5p could act as a fibrosis suppressor in fibrotic diseases including liver fibrosis (Chen et al., 2017; Yang et al., 2019). At the present study, we examined 10 predicted miRNAs in HSCs after kaempferol treatment, which may interact with Jag1. In comparison with the untreated cells, miR-26b-5p was induced by kaempferol, whereas other miRNAs not. miR-26b-5p was shown to be decreased in CCl₄ mice and primary HSC, whereas enhanced Jag1 was found in liver fibrosis. Further studies confirmed that Jag1 was a target of miR-26b-5p. Interestingly, miR-26-5p inhibitor could alleviate the effects of kaempferol on HSC activation inhibition. Kaempferol-inhibited Jag1 protein was also restored by loss of miR-26b-5p. Taken together, kaempferol inhibited HSC activation, at least in part, via miR-26b-5p-mediated Jag1 pathway. However, there were also many limitations in this study. The detailed mechanism of the regulation of kaempferol in miR-26b-5p is still unknown, and further studies are needed in future.

Conclusion

In conclusion, our results demonstrate that kaempferol could inhibit HSC activation via miR-26b-5p/Jag1 axis and Notch pathway. We also provide a new insight of the critical roles of miR-26b-5p-mediated Jag1 in liver fibrosis. Kaempferol may be a novel candidate drug for the treatment of liver fibrosis.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Ethics Statement

The animal study was reviewed and approved by the Experimental Animal Center of Wenzhou Medical University.

Author Contributions

JZ and GZ designed the study. CL, RZ, YZ, and LL analyzed the data. ZL and QT wrote the manuscript. All authors contributed to the article and approved the submitted version.

Funding

The project was supported by the National Natural Science Foundation of China (No. 81873576), Wenzhou Science and Technology Project (Y20210145), the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (No.2020RC081), the project of Wenzhou Medical University Basic Scientific Research (No.KYYW201904), and Zhejiang Province Health Science and Technology Project (2022KY214).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.881855/full#supplementary-material

Abbreviations

CCl4, carbon tetrachloride; Col1A1, alpha-1(I) collagen; Cur, curcumin; Dll1, Delta-like 1; ECM, extracellular matrix; EdU, 5-Ethyny-2ʼ-Deoxyuridine; Hes1, hes family bHLH transcription factor 1; HPS, hypertrophic scar; HSCs, hepatic stellate cells; Jag1, Jagged 1; miRNAs, microRNAs; miR-NC, miRNA negative control; qRT-PCR, quantitative real-time PCR; α-SMA, α-smooth muscle actin.

References

Artavanis-Tsakonas, S., and Muskavitch, M. A. (2010). Notch: the Past, the Present, and the Future. Curr. Top. Dev. Biol. 92, 1–29. doi:10.1016/S0070-2153(10)92001-2

PubMed Abstract | CrossRef Full Text | Google Scholar

Bray, S. J. (2016). Notch Signalling in Context. Nat. Rev. Mol. Cell Biol. 17 (11), 722–735. doi:10.1038/nrm.2016.94

PubMed Abstract | CrossRef Full Text | Google Scholar

Chang, W., Yang, M., Song, L., Shen, K., Wang, H., Gao, X., et al. (2014). Isolation and Culture of Hepatic Stellate Cells from Mouse Liver. Acta Biochim. Biophys. Sin. (Shanghai) 46 (4), 291–298. doi:10.1093/abbs/gmt143

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, X., Xiao, W., Chen, W., Liu, X., Wu, M., Bo, Q., et al. (2017). MicroRNA-26a and -26b Inhibit Lens Fibrosis and Cataract by Negatively Regulating Jagged-1/Notch Signaling Pathway. Cell Death Differ. 24 (11), 1990. doi:10.1038/cdd.2017.147

PubMed Abstract | CrossRef Full Text | Google Scholar

Elovic, E., Etzion, S., and Cohen, S. (2019). MiR-499 Responsive Lethal Construct for Removal of Human Embryonic Stem Cells after Cardiac Differentiation. Sci. Rep. 19 (1), 14490. doi:10.1038/S41598-019-50899-2

PubMed Abstract | CrossRef Full Text | Google Scholar

Faraj, W., Ajouz, H., Mukherji, D., Kealy, G., Shamseddine, A., and Khalife, M. (2011). Inflammatory Pseudo-tumor of the Liver: a Rare Pathological Entity. World J. Surg. Oncol. 9, 5. doi:10.1186/1477-7819-9-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Geisler, F., and Strazzabosco, M. (2015). Emerging Roles of Notch Signaling in Liver Disease. Hepatology 61 (1), 382–392. doi:10.1002/hep.27268

PubMed Abstract | CrossRef Full Text | Google Scholar

Gong, J. H., Shin, D., Han, S. Y., Kim, J. L., and Kang, Y. H. (2012). Kaempferol Suppresses Eosionphil Infiltration and Airway Inflammation in Airway Epithelial Cells and in Mice with Allergic Asthma. J. Nutr. 142 (1), 47–56. doi:10.3945/jn.111.150748

PubMed Abstract | CrossRef Full Text | Google Scholar

Guo, H., Ren, F., Zhang, L., Zhang, X., Yang, R., Xie, B., et al. (2016). Kaempferol Induces Apoptosis in HepG2 Cells via Activation of the Endoplasmic Reticulum Stress Pathway. Mol. Med. Rep. 13 (3), 2791–2800. doi:10.3892/mmr.2016.4845

PubMed Abstract | CrossRef Full Text | Google Scholar

Kim, T. W., Lee, S. Y., Kim, M., Cheon, C., and Ko, S. G. (2018). Kaempferol Induces Autophagic Cell Death via IRE1-JNK-CHOP Pathway and Inhibition of G9a in Gastric Cancer Cells. Cell Death Dis. 9 (9), 875. doi:10.1038/s41419-018-0930-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Kitano, M., and Bloomston, P. M. (2016). Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis. J. Clin. Med. 5 (3). doi:10.3390/jcm5030038

PubMed Abstract | CrossRef Full Text | Google Scholar

Kovall, R. A., Gebelein, B., Sprinzak, D., and Kopan, R. (2017). The Canonical Notch Signaling Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. Dev. Cell 41 (3), 228–241. doi:10.1016/j.devcel.2017.04.001

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, H., Yang, L., Zhang, Y., and Gao, Z. (2016). Kaempferol Inhibits Fibroblast Collagen Synthesis, Proliferation and Activation in Hypertrophic Scar via Targeting TGF-β Receptor Type I. Biomed. Pharmacother. 83, 967–974. doi:10.1016/j.biopha.2016.08.011

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, X. X., Li, X. J., Zhang, B., Liang, Y. J., Zhou, C. X., Cao, D. X., et al. (2011). MicroRNA-26b Is Underexpressed in Human Breast Cancer and Induces Cell Apoptosis by Targeting SLC7A11. FEBS Lett. 585 (9), 1363–1367. doi:10.1016/j.febslet.2011.04.018

PubMed Abstract | CrossRef Full Text | Google Scholar

Ren, J., Lu, Y., Qian, Y., Chen, B., Wu, T., Ji, G., et al. (2019). Recent Progress Regarding Kaempferol for the Treatment of Various Diseases. Exp. Ther. Med. 18 (4), 2759–2776. doi:10.3892/etm.2019.7886

PubMed Abstract | CrossRef Full Text | Google Scholar

Rho, H. S., Ghimeray, A. K., Yoo, D. S., Ahn, S. M., Kwon, S. S., Lee, K. H., et al. (2011). Kaempferol and Kaempferol Rhamnosides with Depigmenting and Anti-inflammatory Properties. Molecules 16 (4), 3338–3344. doi:10.3390/molecules16043338

PubMed Abstract | CrossRef Full Text | Google Scholar

Sawitza, I., Kordes, C., Reister, S., and Häussinger, D. (2009). The Niche of Stellate Cells within Rat Liver. Hepatology 50 (5), 1617–1624. doi:10.1002/hep.23184

PubMed Abstract | CrossRef Full Text | Google Scholar

Sharma, S., Pavlasova, G., Seda, V., Cerna, K., Vojackova, E., Filip, D., et al. (2021). miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR Inhibitors. Blood 137 (18), 2481–2494. doi:10.1182/blood.2020005627

PubMed Abstract | CrossRef Full Text | Google Scholar

Siebel, C., and Lendahl, U. (2017). Notch Signaling in Development, Tissue Homeostasis, and Disease. Physiol. Rev. 97 (4), 1235–1294. doi:10.1152/physrev.00005.2017

PubMed Abstract | CrossRef Full Text | Google Scholar

Tang, G., Weng, Z., Song, J., and Chen, Y. (2017). Reversal Effect of Jagged1 Signaling Inhibition on CCl4-Induced Hepatic Fibrosis in Rats. Oncotarget 8 (37), 60778–60788. doi:10.18632/oncotarget.18484

PubMed Abstract | CrossRef Full Text | Google Scholar

Tokunaga, Y., Osawa, Y., Ohtsuki, T., Hayashi, Y., Yamaji, K., Yamane, D., et al. (2017). Selective Inhibitor of Wnt/β-Catenin/CBP Signaling Ameliorates Hepatitis C Virus-Induced Liver Fibrosis in Mouse Model. Sci. Rep. 7 (1), 325. doi:10.1038/s41598-017-00282-w

PubMed Abstract | CrossRef Full Text | Google Scholar

Ueha, S., Shand, F. H., and Matsushima, K. (2012). Cellular and Molecular Mechanisms of Chronic Inflammation-Associated Organ Fibrosis. Front. Immunol. 3, 71. doi:10.3389/fimmu.2012.00071

PubMed Abstract | CrossRef Full Text | Google Scholar

Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., et al. (2012). Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. Gastroenterology 143 (6), 1660–e7. doi:10.1053/j.gastro.2012.09.002

PubMed Abstract | CrossRef Full Text | Google Scholar

Xu, T., Huang, S., Huang, Q., Ming, Z., Wang, M., Li, R., et al. (2019). Kaempferol Attenuates Liver Fibrosis by Inhibiting Activin Receptor-like Kinase 5. J. Cell Mol. Med. 23 (9), 6403–6410. doi:10.1111/jcmm.14528

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, L., Dong, C., Yang, J., Yang, L., Chang, N., Qi, C., et al. (2019). MicroRNA-26b-5p Inhibits Mouse Liver Fibrogenesis and Angiogenesis by Targeting PDGF Receptor-Beta. Mol. Ther. Nucleic Acids 16, 206–217. doi:10.1016/j.omtn.2019.02.014

PubMed Abstract | CrossRef Full Text | Google Scholar

Yu, F., Chen, B., Dong, P., and Zheng, J. (2017). HOTAIR Epigenetically Modulates PTEN Expression via MicroRNA-29b: A Novel Mechanism in Regulation of Liver Fibrosis. Mol. Ther. 25 (1), 205–217. doi:10.1016/j.ymthe.2016.10.015

PubMed Abstract | CrossRef Full Text | Google Scholar

Zeng, W., Sun, Z., Lai, Z., Yang, S., Chen, H., Yang, X., et al. (2019). Determination of the MiRNAs Related to Bean Pyralid Larvae Resistance in Soybean Using Small RNA and Transcriptome Sequencing. Int. J. Mol. Sci. 20 (12). doi:10.3390/ijms20122966

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, F., Zhang, Z., Chen, L., Kong, D., Zhang, X., Lu, C., et al. (2014). Curcumin Attenuates Angiogenesis in Liver Fibrosis and Inhibits Angiogenic Properties of Hepatic Stellate Cells. J. Cell Mol. Med. 18 (7), 1392–1406. doi:10.1111/jcmm.12286

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, L., Jiang, H., Zhang, Y., Wang, C., Xia, X., and Sun, Y. (2020). GR Silencing Impedes the Progression of Castration-Resistant Prostate Cancer through the JAG1/NOTCH2 Pathway via Up-Regulation of microRNA-143-3p. Cancer Biomark. 28 (4), 483–497. doi:10.3233/CBM-191271

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, M., Yuan, S. Z., Sun, H., Sun, L., Zhou, D., and Yan, J. (2020). miR-199b-5p Promoted Chondrogenic Differentiation of C3H10T1/2 Cells by Regulating JAG1. J. Tissue Eng. Regen. Med. 14 (11), 1618–1629. doi:10.1002/term.3122

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhou, G., Li, C., Zhan, Y., Zhang, R., Lv, B., Geng, W., et al. (2020). Pinostilbene Hydrate Suppresses Hepatic Stellate Cell Activation via Inhibition of miR-17-5p-Mediated Wnt/β-Catenin Pathway. Phytomedicine 79, 153321. doi:10.1016/j.phymed.2020.153321

PubMed Abstract | CrossRef Full Text | Google Scholar